Morningstar

Adicet Bio Gets FDA Clearance For Phase 1 Trial of Prostate Cancer Treatment

Provided by Dow Jones

By Elias Schisgall 




  Adicet Bio said the Food and Drug Administration greenlit a Phase 1 trial of a potential treatment for prostate cancer. 



  The clinical-stage biotechnology company said the FDA cleared its investigational new drug application for ADI-212, a treatment for metastatic castration-resistant prostate cancer. The company said it plans to initiate Phase 1 enrollment in the fourth quarter. 



  "ADI-212 marks an important milestone in Adicet's strategy to address the complexity of solid tumors and represents an important addition to our portfolio of allogeneic gamma delta 1 cell therapies and in vivo CAR T programs," Chief Scientific Officer Blake Aftab said. 



  Shares of Adicet gained 3.8% to $9.35 in after-hours trading on Thursday. The Stock closed up 0.7% at $9.01, up 7% this year. 





  Write to Elias Schisgall at elias.schisgall@wsj.com 





  (END) Dow Jones Newswires



  August 27, 2026 17:12 ET (21:12 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
 
Plus, a deep dive on SpaceX’s bid to challenge US telecoms. 
 
 
David Sekera, CFA and Sarah Hansen 
 
 
 
Why This Vanguard ETF Is One of the Best
 
Vanguard Total International Stock is appealing for several reasons. 
 
 
Zachary Evens 
 
 
 
2 Undervalued Stocks to Buy With Long-Term Growth Ahead
 
Defense spending and booming data center demand could provide powerful tailwinds for these 4-star stocks. 
 
 
David Sekera, CFA, Sarah Hansen, and Jess Bebel 
 
 
 
The Market May Be Too Pessimistic About This 4-Star Dividend Stock
 
Despite a looming patent cliff, a strong drug pipeline and 4.1% yield give investors reasons for optimism. 
 
 
Karen Andersen, CFA 
 
 
 
The Best AI Stocks to Buy Now
 
Artificial intelligence stocks continue to attract investors, thanks to industry momentum and appealing valuations. 
 
 
Tori Brovet 
 
 
 
 

			Sponsor Center